NCT01776437View on ClinicalTrials.gov

Study of BMN 673, a PARP Inhibitor, in Healthy Adult Male Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

February 28, 2013

Primary Completion Date

May 31, 2013

Study Completion Date

July 31, 2013

Conditions
Human Volunteers
Interventions
DRUG

BMN 673

500mcg dose of BMN 673, 2 discrete single doses separated by 21 days

Trial Locations (1)

47710

Covance Clinical Research Unit Inc., Evansville

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT01776437 - Study of BMN 673, a PARP Inhibitor, in Healthy Adult Male Volunteers | Biotech Hunter | Biotech Hunter